No recent analyst price targets found for LYT.
Latest News for LYT
PureTech Announces Orphan Drug Designations Granted by the U.S. Food and Drug Administration and European Commission for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis
BOSTON--(BUSINESS WIRE)--PureTech Announces Orphan Drug Designations Granted by the U.S. Food and Drug Administration and European Commission for Deupirfenidone in IPF.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for LYT.
Senate Trading
No Senate trades found for LYT.
U.S. House Trading
No House trades found for LYT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.